Open Label Study of Long Term Safety Evaluation of Alirocumab

NCT01954394 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

986

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Alirocumab
DRUG: Lipid-Modifying Therapy (LMT)

Sponsor

Sanofi

Collaborators

[object Object]